Abstract: A method including executing a logical computing element (LCE) on a server. Worker LCEs are executed on the server. A first electronic file comprising geometry data in a first data structure is received at the controller LCE. An available worker LCE is identified, by the controller LCE, as an in-use worker LCE from among the worker LCEs. The geometry data is imported by the in-use worker LCE. A job instance is established by the in-use worker LCE. A rendering engine is launched by the in-use worker LCE. The rendering engine generates, for the job instance and using the geometry data, a dataset file in a second data structure different than the first data structure. The dataset file is returned by the in-use worker LCE to the controller LCE. The dataset file is returned by the controller LCE to a remote computer.

Abstract: Embodiments disclosed herein may include a method for developing a photopatterned metal oxo photoresist. In an embodiment, the method may include pre-treating the photopatterned metal oxo photoresist with a pre-treatment process, developing the photopatterned metal oxo photoresist with a thermal dry develop process to selectively remove a portion of the photopatterned metal oxo photoresist and form a resist mask. In an embodiment, the thermal dry develop process includes a first sub-operation, and a second sub-operation that is different than the first sub-operation. In an embodiment, the process further includes post-treating the resist mask with a post-treatment process.

Abstract: Spacecraft servicing devices or pods and related methods may include a body configured to be deployed from a host spacecraft at a location adjacent a target spacecraft and at least one spacecraft servicing component configured to perform at least one servicing operation on the target spacecraft.

Abstract: Disclosed herein is a system for treating a magnesium or a magnesium alloy substrate comprising: a first pretreatment composition comprising a fluorometallic acid and free fluoride in an amount of 10 ppm to 500 ppm based on total weight of the first pretreatment composition and having a pH of 1.0 to 4.0; and a second pretreatment composition comprising a lanthanide series metal, the second pretreatment composition being substantially free of peroxide. Also disclosed are methods of treating a magnesium or magnesium alloy substrate. Treated magnesium and magnesium alloy substrates also are disclosed.

Abstract: The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O?M+), —P(O)(O?M+)2 and —P(O)(O?)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

Abstract: Systems and methods for providing supplemental information with a response to a command are provided herein. In some embodiments, audio data representing a spoken command may be received by a cloud-based information system. A response to the command may be retrieved from a category related to the context of the command. A supplemental information database may also be provided that is pre-populated with supplemental information related to an individual having a registered account on the cloud-based information system. In response to retrieving the response to the command, supplemental information may be selected from the supplemental information database to be appended to the response to the command. A message may then be generated including the response and the supplemental information appended thereto, which in turn may be converted into audio data representing the message, which may be sent to a voice-controlled electronic device of the individual.

Abstract: A container having a base and a lid is provided. The lid may be rotatable about a hinge from a closed configuration to an open configuration and may be secured, via one or more latching assemblies. The latching assembly may comprise a latch body, a locking member, a biasing member, and an activating member. Additional features of the container may include handles and strength increasing features. The base and lid may also feature attachment points for various accessories. A carry strap may attach to the base of the container to allow a user to lift and carry the container. The container may also have a wheels attached to the bottom portion and/or across the bottom portion to one side of the sidewall structure. In addition, in exemplary containers with wheels, a pull handle may be attached to a side opposite the wheels. The lid may include a lid support member that can act as a molle board to releasably secure items to the lid support member while also providing structural support to the lid.

Abstract: An active fiber stretcher assembly can be used for data acquisition systems. A time-break signal can be detected that coincides with a seismic event emitted from a seismic controller. A predetermined waveform can be generated in response to detecting the time-break signal. The predetermined waveform may be encoded onto a fiber optic cable using a fiber stretcher. A data acquisition system connected to the fiber optic cable may detect the predetermined waveform on the fiber optic cable and initiate acquisition operations including: receiving, during the seismic event, light signals returning from a portion of the fiber optic cable in a subterranean environment; determining one or more characteristics of the subterranean environment from the light signals; and storing the one or more characteristics.

Abstract: A test tool attached to test string comprising a fluid conduit is deployed to a test position within a wellbore. The deployment includes hydraulically isolating a portion of the wellbore proximate the test tool to form an isolation zone containing the test position. A fluid inflow test is performed within the isolation zone and an initial formation property and a fluid property are determined based on the fluid inflow test. A fluid injection test is performed within the isolation zone including applying an injection fluid through the test string into the isolation zone, wherein the flow rate or pressure of the injection fluid application is determined based, at least in part, on the at least one of the formation property and fluid property.

Abstract: A medical product includes a bladder, a filtration device, and a sterile product concentrate. The bladder has a perimeter seal and defining a sterile chamber. The filtration device includes a stem and a filter membrane disposed in line with the stem. The stem extends through the perimeter seal and has an inlet end accessible from outside of the perimeter seal and an outlet end in fluid communication with the sterile chamber. The filter membrane can have a nominal pore size in a range of approximately 0.1 ?m to approximately 0.5 ?m, wherein the filter membrane is shaped as a hollow fiber with a wall and pores residing in the wall of the fiber. The sterile product concentrate is disposed in the sterile chamber and adapted to be reconstituted by the introduction of a pharmaceutical fluid into the chamber through the filtration device.

Abstract: Disclosed are multi-ply tissue products comprising a non-crosslinked binder that are durable and dispersible. The products generally have a Slosh time less than 2 minutes, such as less than about 60 seconds, such as less than about 45 seconds. Surprisingly, the foregoing Slosh times are achieved despite the tissue products having relatively high cross-machine direction (CD) wet tensile strength, such as greater than about 100 g/3?. Typically, increasing wet tensile strength, particularly wet CD tensile strength, negatively effects dispersability and increases Slosh time. Despite this trend, the present invention surprisingly provides a tissue product having a relatively high degree of wet strength and good dispersability.

Abstract: The disclosure features macrocyclic compounds, alone and in combination with other therapeutic agents, as well as pharmaceutical compositions and protein complexes thereof, capable of modulating biological processes including RAS and RAS-RAF inhibition, and their uses in the treatment of cancers.

Abstract: Filaments that contain a filament-forming material and an additive, nonwoven webs, and methods for making such filaments are provided.

Abstract: A vehicle closure module overtravel accommodating system includes a closure module of a vehicle. The closure module is pivotably coupled to a vehicle frame and is configured to pivot relative to the vehicle frame back-and-forth between a closed position and an open position. The system further includes a breakaway mount of the vehicle, and a bumper assembly having a head disposed on a base. The bumper assembly engages the breakaway mount to secure the bumper assembly within the vehicle.

Abstract: The following description is directed to a configurable logic platform. In one example, a configurable logic platform includes host logic and a reconfigurable logic region. The reconfigurable logic region can include logic blocks that are configurable to implement application logic. The host logic can be used for encapsulating the reconfigurable logic region. The host logic can include a host interface for communicating with a processor. The host logic can include a management function accessible via the host interface. The management function can be adapted to cause the reconfigurable logic region to be configured with the application logic in response to an authorized request from the host interface. The host logic can include a data path function accessible via the host interface. The data path function can include a layer for formatting data transfers between the host interface and the application logic.

Abstract: Certain aspects of the present disclosure provide techniques for providing an augmented reality user interface, including: receiving, by an image sensor of an electronic device, an image of a physical document; determining a document type associated with the physical document by performing image recognition on the image of the physical document; determining an augmented reality template to display on a display of the electronic device; displaying the augmented reality template on the display of the electronic device, wherein the augmented reality template is aligned in three dimensions with the physical document; determining a distance between the physical document and the electronic device; and enabling one or more interactive user interface elements within the augmented reality template displayed on the display of the electronic device if the determined distance between the physical document and the electronic device is less than a threshold distance.

Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.

Abstract: Described herein are methods of eliciting an immune response in human subject in need thereof, the methods including transdermally delivering to the human subject a composition comprising particles, the composition contained in a housing of a microneedle patch device, wherein transdermally delivering includes transdermally delivering an initial dose; transdermally delivering a booster dose within 4-6 weeks of the initial dose; and transdermally delivering a subsequent dose at 1 year or more after delivering the booster dose, wherein no dose is given between the booster dose and the subsequent dose. The composition includes particles including an antigenic multilayer film.